Regeneron Pharmaceuticals Inc, Mitsubishi Tanabe Pharma deal

Regeneron granted Mitsubishi exclusive rights to develop and commercialize fasinumab ( REGN475) in Japan, South Korea, Taiwan, Indonesia, Thailand, Philippines, Malaysia Singapore, Vietnam, Myanmar and Sri Lanka. The deal does not include China. The mAb against nerve growth factor (NGF) is in a Phase IIb/III trial to treat pain associated with osteoarthritis (OA) of the knee or hip. ...